デフォルト表紙
市場調査レポート
商品コード
1553590

肺腺がん治療の市場規模、シェア、動向分析レポート:治療別、最終用途別、地域別、セグメント別予測、2024年~2030年

Lung Adenocarcinoma Treatment Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy, Immunotherapy), By End-use (Hospitals, Specialty Clinics), By Region, And Segment Forecasts, 2024 - 2030

出版日: | 発行: Grand View Research | ページ情報: 英文 120 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=153.05円
肺腺がん治療の市場規模、シェア、動向分析レポート:治療別、最終用途別、地域別、セグメント別予測、2024年~2030年
出版日: 2024年08月23日
発行: Grand View Research
ページ情報: 英文 120 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

肺腺がん治療市場の成長と動向:

Grand View Research社の最新レポートによると、世界の肺腺がん治療の市場規模は2030年までに111億8,000万米ドルに達すると予測され、予測期間中に10.68%のCAGRで成長すると予測されています。

この市場は、非小細胞肺がん(NSCLC)のサブタイプである肺腺がんの管理と治療を目的とした幅広い治療オプション、技術、サービスを提供しています。

特定の地域における喫煙率の上昇、大気汚染や職業上の危険などの環境要因が市場成長の主な促進要因です。肺腺がんと診断される人が増えるにつれて、効果的な治療オプションに対する需要も高まっています。

肺がんの症状や危険因子に関する意識の高まりは、市場に大きな影響を与えています。禁煙と早期発見についての啓蒙を目的とした公衆衛生キャンペーンにより、症状を経験した後すぐに医療機関を受診する人が増加しました。

2023年10月、ブリストル・マイヤーズスクイブ社は、進行非小細胞肺がんに対するKRASG12C阻害剤KRAZATI(アダグラシブ)を含む総額48億米ドル、偶発的価値権により58億米ドルの株式価値でミラティ社を買収しました。

肺腺がん治療市場レポートハイライト:

  • 治療法別では、化学療法が2023年の市場を独占しました。個別化医療の登場により、肺腺がん患者の特定の遺伝子変異に合わせた標的化学療法レジメンが開発され、治療効果と患者の転帰がさらに向上しました。
  • 最終用途別では、病院が2023年に64.34%の最大売上シェアで市場を独占しました。肺腺がんの世界の有病率の増加は、化学療法、標的療法、外科的処置など、病院でしか実施できない複雑な介入を患者が必要とするため、入院に対する需要の高まりにつながっています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 肺腺がん治療市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 肺腺がん治療市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 肺腺がん治療市場:治療別推定・動向分析

  • 世界の肺腺がん治療市場:治療ダッシュボード
  • 世界の肺腺がん治療市場:治療変動分析
  • 世界の肺腺がん治療市場:治療別収益
  • 化学療法
  • 標的療法
  • 免疫療法
  • 放射線治療
  • その他

第5章 肺腺がん治療市場:最終用途別推定・動向分析

  • 世界の肺腺がん治療市場:最終用途ダッシュボード
  • 世界の肺腺がん治療市場:最終用途変動分析
  • 世界の肺腺がん治療市場:最終用途別収益
  • 病院
  • 専門クリニック
  • その他

第6章 肺腺がん治療市場:治療および最終用途別の地域推定・動向分析

  • 地域ダッシュボード
  • 市場規模、予測動向分析、2018年から2030年:
  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ

第7章 競合情勢

  • 企業/競合の分類
  • ベンダー情勢
    • 主要販売代理店およびチャネルパートナーのリスト
    • 主要企業の市場シェア分析、2023年
    • Pfizer
    • AstraZeneca
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • Boehringer Ingelheim International GmbH
    • Novartis AG
    • Merck KGaA(EMD Serono)
    • AbbVie Inc.
    • Astellas Pharma Inc.
    • F. Hoffmann-La Roche
図表

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America Lung adenocarcinoma treatment market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America Lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 4 North America Lung adenocarcinoma treatment market, by End Use, 2018 - 2030 (USD Million)
  • Table 5 U.S. Lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 6 U.S. Lung adenocarcinoma treatment market, by End Use, 2018 - 2030 (USD Million)
  • Table 7 Canada Lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 8 Canada Lung adenocarcinoma treatment market, by End Use, 2018 - 2030 (USD Million)
  • Table 9 Mexico Lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 10 Mexico Lung adenocarcinoma treatment market, by End Use, 2018 - 2030 (USD Million)
  • Table 11 Europe Lung adenocarcinoma treatment market, by region, 2018 - 2030 (USD Million)
  • Table 12 Europe Lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 13 Europe Lung adenocarcinoma treatment market, by End Use, 2018 - 2030 (USD Million)
  • Table 14 Germany Lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 15 Germany Lung adenocarcinoma treatment market, by End Use, 2018 - 2030 (USD Million)
  • Table 16 UK Lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 17 UK Lung adenocarcinoma treatment market, by End Use, 2018 - 2030 (USD Million)
  • Table 18 France Lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 19 France Lung adenocarcinoma treatment market, by End Use, 2018 - 2030 (USD Million)
  • Table 20 Italy Lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 21 Italy Lung adenocarcinoma treatment market, by End Use, 2018 - 2030 (USD Million)
  • Table 22 Spain Lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 23 Spain Lung adenocarcinoma treatment market, by End Use, 2018 - 2030 (USD Million)
  • Table 24 Denmark Lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 25 Denmark Lung adenocarcinoma treatment market, by End Use, 2018 - 2030 (USD Million)
  • Table 26 Sweden Lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 27 Sweden Lung adenocarcinoma treatment market, by End Use, 2018 - 2030 (USD Million)
  • Table 28 Norway Lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 29 Norway Lung adenocarcinoma treatment market, by End Use, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific Lung adenocarcinoma treatment market, by region, 2018 - 2030 (USD Million)
  • Table 31 Asia Pacific Lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 32 Asia Pacific Lung adenocarcinoma treatment market, by End Use, 2018 - 2030 (USD Million)
  • Table 33 China Lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 34 China Lung adenocarcinoma treatment market, by End Use, 2018 - 2030 (USD Million)
  • Table 35 Japan Lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 36 Japan Lung adenocarcinoma treatment market, by End Use, 2018 - 2030 (USD Million)
  • Table 37 India Lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 38 India Lung adenocarcinoma treatment market, by End Use, 2018 - 2030 (USD Million)
  • Table 39 South Korea Lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 40 South Korea Lung adenocarcinoma treatment market, by End Use, 2018 - 2030 (USD Million)
  • Table 41 Australia Lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 42 Australia Lung adenocarcinoma treatment market, by End Use, 2018 - 2030 (USD Million)
  • Table 43 Thailand Lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 44 Thailand Lung adenocarcinoma treatment market, by End Use, 2018 - 2030 (USD Million)
  • Table 45 Latin America Lung adenocarcinoma treatment market, by region, 2018 - 2030 (USD Million)
  • Table 46 Latin America Lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 47 Latin America Lung adenocarcinoma treatment market, by End Use, 2018 - 2030 (USD Million)
  • Table 48 Brazil Lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 49 Brazil Lung adenocarcinoma treatment market, by End Use, 2018 - 2030 (USD Million)
  • Table 50 Argentina Lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 51 Argentina Lung adenocarcinoma treatment market, by End Use, 2018 - 2030 (USD Million)
  • Table 52 MEA Lung adenocarcinoma treatment market, by region, 2018 - 2030 (USD Million)
  • Table 53 MEA Lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 54 MEA Lung adenocarcinoma treatment market, by End Use, 2018 - 2030 (USD Million)
  • Table 55 South Africa Lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 56 South Africa Lung adenocarcinoma treatment market, by End Use, 2018 - 2030 (USD Million)
  • Table 57 Saudi Arabia Lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 58 Saudi Arabia Lung adenocarcinoma treatment market, by End Use, 2018 - 2030 (USD Million)
  • Table 59 UAE Lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 60 UAE Lung adenocarcinoma treatment market, by End Use, 2018 - 2030 (USD Million)
  • Table 61 Kuwait Lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 62 Kuwait Lung adenocarcinoma treatment market, by End Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Market research approaches
  • Fig. 4 QFD modeling for market share assessment
  • Fig. 5 Market formulation & validation
  • Fig. 6 Lung adenocarcinoma treatment market: market outlook
  • Fig. 7 Lung adenocarcinoma treatment competitive insights
  • Fig. 8 Parent market outlook
  • Fig. 9 Related/ancillary market outlook
  • Fig. 10 Lung adenocarcinoma treatment market driver impact
  • Fig. 11 Lung adenocarcinoma treatment market restraint impact
  • Fig. 12 Lung adenocarcinoma treatment market: Treatment movement analysis
  • Fig. 13 Lung adenocarcinoma treatment market: Treatment outlook and key takeaways
  • Fig. 14 Chemotherapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 15 Targeted therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 16 Immunotherapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 17 Radiation therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 18 Other market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Lung adenocarcinoma treatment market: End Use movement analysis
  • Fig. 20 Lung adenocarcinoma treatment market: End Use outlook and key takeaways
  • Fig. 21 Hospitals market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Specialty clinics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Other market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Global Lung adenocarcinoma treatment market: Regional movement analysis
  • Fig. 25 Global Lung adenocarcinoma treatment market: Regional outlook and key takeaways
  • Fig. 26 Global Lung adenocarcinoma treatment market share and leading players
  • Fig. 27 North America, by country
  • Fig. 28 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 U.S. key country dynamics
  • Fig. 30 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Canada key country dynamics
  • Fig. 32 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Mexico key country dynamics
  • Fig. 34 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 UK key country dynamics
  • Fig. 37 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Germany key country dynamics
  • Fig. 39 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 France key country dynamics
  • Fig. 41 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Italy key country dynamics
  • Fig. 43 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Spain key country dynamics
  • Fig. 45 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Denmark key country dynamics
  • Fig. 47 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Sweden key country dynamics
  • Fig. 49 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Norway key country dynamics
  • Fig. 51 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 China key country dynamics
  • Fig. 54 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Japan key country dynamics
  • Fig. 56 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 India key country dynamics
  • Fig. 58 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Thailand key country dynamics
  • Fig. 60 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 South Korea key country dynamics
  • Fig. 62 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Australia key country dynamics
  • Fig. 64 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Brazil key country dynamics
  • Fig. 67 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Argentina key country dynamics
  • Fig. 69 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 South Africa key country dynamics
  • Fig. 72 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Saudi Arabia key country dynamics
  • Fig. 74 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 UAE key country dynamics
  • Fig. 76 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Kuwait key country dynamics
  • Fig. 78 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Market share of key market players- Lung adenocarcinoma treatment market
目次
Product Code: GVR-4-68040-428-6

Lung Adenocarcinoma Treatment Market Growth & Trends:

The global lung adenocarcinoma treatment market size is anticipated to reach USD 11.18 billion by 2030 and is projected to grow at a CAGR of 10.68% during the forecast period, according to a new report by Grand View Research, Inc. This market offers a range of therapeutic options, technologies, and services aimed at managing and treating lung adenocarcinoma, which is a subtype of non-small cell lung cancer (NSCLC).

The rise in smoking rates in certain regions and environmental factors such as air pollution and occupational hazards are key growth drivers for market growth. As more individuals are diagnosed with lung adenocarcinoma, there is a corresponding demand for effective treatment options.

Increased awareness about lung cancer symptoms and risk factors has significantly influenced the market. Public health campaigns aimed at educating populations about smoking cessation and early detection led to more individuals seeking medical attention sooner after experiencing symptoms.

In October 2023, Bristol Myers Squibb acquired Mirati for USD 58.00 per share, totaling USD 4.8 billion in equity value, potentially rising to USD 5.8 billion with contingent value rights, including KRAZATI (adagrasib), a KRASG12C inhibitor for advanced non-small cell lung cancer.

Lung Adenocarcinoma Treatment Market Report Highlights:

  • On the basis of treatment, chemotherapy dominated the market in 2023. The advent of personalized medicine led to the development of targeted chemotherapy regimens tailored to specific genetic mutations found in lung adenocarcinoma patients, further enhancing treatment efficacy and patient outcomes.
  • On the basis of end use, hospitals dominated the market with the largest revenue share of 64.34% in 2023. The increasing prevalence of lung adenocarcinoma globally has led to a higher demand for hospitalization, as patients require complex interventions such as chemotherapy, targeted therapy, and surgical procedures that can only be performed in a hospital setting.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Treatment
    • 1.2.2. End Use
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Treatment Outlook
    • 2.2.2. End Use Outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Lung Adenocarcinoma Treatment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. The increasing incidence of lung cancer
      • 3.2.1.2. Advancements in targeted therapies and immunotherapies
      • 3.2.1.3. The growing emphasis on personalized medicine
      • 3.2.1.4. The rising demand for early detection and screening programs
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of treatments
      • 3.2.2.2. Limited availability of skilled healthcare professionals
  • 3.3. Lung Adenocarcinoma Treatment Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Lung Adenocarcinoma Treatment Market: Treatments Estimates & Trend Analysis

  • 4.1. Global Lung Adenocarcinoma Treatment Market: Treatments Dashboard
  • 4.2. Global Lung Adenocarcinoma Treatment Market: Treatments Movement Analysis
  • 4.3. Global Lung Adenocarcinoma Treatment Market by Treatments, Revenue
  • 4.4. Chemotherapy
    • 4.4.1. Chemotherapy market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Targeted Therapy
    • 4.5.1. Targeted Therapy market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Immunotherapy
    • 4.6.1. Immunotherapy market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Radiation Therapy
    • 4.7.1. Radiation Therapy market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. Other
    • 4.8.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Lung Adenocarcinoma Treatment Market: End Use Estimates & Trend Analysis

  • 5.1. Global Lung Adenocarcinoma Treatment Market: End Use Dashboard
  • 5.2. Global Lung Adenocarcinoma Treatment Market: End Use Movement Analysis
  • 5.3. Global Lung Adenocarcinoma Treatment Market Estimates and Forecasts, By End Use, Revenue (USD Million)
  • 5.4. Hospitals
    • 5.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Specialty Clinics
    • 5.5.1. Specialty Clinics market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Other
    • 5.6.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Lung Adenocarcinoma Treatment Market: Regional Estimates & Trend Analysis by Treatments, and End Use

  • 6.1. Regional Dashboard
  • 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.3. North America
    • 6.3.1. U.S.
      • 6.3.1.1. Key country dynamics
      • 6.3.1.2. Regulatory framework/ reimbursement structure
      • 6.3.1.3. Competitive scenario
      • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.2. Canada
      • 6.3.2.1. Key country dynamics
      • 6.3.2.2. Regulatory framework/ reimbursement structure
      • 6.3.2.3. Competitive scenario
      • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.3. Mexico
      • 6.3.3.1. Key country dynamics
      • 6.3.3.2. Regulatory framework/ reimbursement structure
      • 6.3.3.3. Competitive scenario
      • 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Key country dynamics
      • 6.4.1.2. Regulatory framework/ reimbursement structure
      • 6.4.1.3. Competitive scenario
      • 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Regulatory framework/ reimbursement structure
      • 6.4.2.3. Competitive scenario
      • 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. France
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Regulatory framework/ reimbursement structure
      • 6.4.3.3. Competitive scenario
      • 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Key country dynamics
      • 6.4.4.2. Regulatory framework/ reimbursement structure
      • 6.4.4.3. Competitive scenario
      • 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Key country dynamics
      • 6.4.5.2. Regulatory framework/ reimbursement structure
      • 6.4.5.3. Competitive scenario
      • 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.6. Norway
      • 6.4.6.1. Key country dynamics
      • 6.4.6.2. Regulatory framework/ reimbursement structure
      • 6.4.6.3. Competitive scenario
      • 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.7. Sweden
      • 6.4.7.1. Key country dynamics
      • 6.4.7.2. Regulatory framework/ reimbursement structure
      • 6.4.7.3. Competitive scenario
      • 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.8. Denmark
      • 6.4.8.1. Key country dynamics
      • 6.4.8.2. Regulatory framework/ reimbursement structure
      • 6.4.8.3. Competitive scenario
      • 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. China
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. India
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework/ reimbursement structure
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.5. South Korea
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Regulatory framework/ reimbursement structure
      • 6.5.5.3. Competitive scenario
      • 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.6. Thailand
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Regulatory framework/ reimbursement structure
      • 6.5.6.3. Competitive scenario
      • 6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.2. Argentina
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. MEA
    • 6.7.1. South Africa
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.2. Saudi Arabia
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company/Competition Categorization
  • 7.2. Vendor Landscape
    • 7.2.1. List of key distributors and channel partners
    • 7.2.2. Key company market share analysis, 2023
    • 7.2.3. Pfizer
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. AstraZeneca
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. Bristol-Myers Squibb Company
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. Eli Lilly and Company
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. Boehringer Ingelheim International GmbH
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. Novartis AG
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives
    • 7.2.9. Merck KGaA (EMD Serono)
      • 7.2.9.1. Company overview
      • 7.2.9.2. Financial performance
      • 7.2.9.3. Product benchmarking
      • 7.2.9.4. Strategic initiatives
    • 7.2.10. AbbVie Inc.
      • 7.2.10.1. Company overview
      • 7.2.10.2. Financial performance
      • 7.2.10.3. Product benchmarking
      • 7.2.10.4. Strategic initiatives
    • 7.2.11. Astellas Pharma Inc.
      • 7.2.11.1. Company overview
      • 7.2.11.2. Financial performance
      • 7.2.11.3. Product benchmarking
      • 7.2.11.4. Strategic initiatives
    • 7.2.12. F. Hoffmann-La Roche
      • 7.2.12.1. Company overview
      • 7.2.12.2. Financial performance
      • 7.2.12.3. Product benchmarking
      • 7.2.12.4. Strategic initiatives